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Abstract: Cancer is currently a major public health problem and, as such, emerging research is making significant pro-
gress in identifying major players in its biology. One recent topic of interest involves microRNAs (miRNAs) which are 
small, non-coding RNA molecules that inhibit gene expression post-transcriptionally. They accomplish this by binding to 
the 3’ untranslated region (3’UTR) of target messengerRNA (mRNA), resulting in either their degradation or inhibition of 
translation, depending on the degree of complementary base pairing. They are transcribed by RNA polymerase II and are 
formed into mature miRNAs via two steps, each catalyzed by a different ribonuclease III (RNaseIII). Cross-species com-
parisons demonstrate that miRNAs are evolutionarily conserved and play important roles in a wide array of normal bio-
logical processes. Importantly, aberrant miRNA expression is correlated with human disease, especially in the develop-
ment of cancer. Recent research has identified targets and functions of miRNAs, illustrating that some are oncogenic in 
nature while others show tumor suppressor activity. The miRNAs have also been characterized as having high potential in 
the clinical arena and, as such, have been a target for exploitation toward cancer therapy. Not only has it been shown that 
miRNA expression profiles may prove useful as diagnostic and prognostic markers in cancer, various miRNA-based 
therapies show promise as well. It is anticipated that further research will elucidate the benefits of using miRNAs as clini-
cal agents in the battle against cancer and other chronic diseases.  
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INTRODUCTION 
  Cancer is currently one of the leading causes of death in 
the United States and other developed countries, and thus has 
caused many public health concerns in the present and will 
continue as a major health concern in the future unless sig-
nificant breakthroughs are made in the therapeutic arenas for 
the treatment of not only cancers, but other chronic diseases 
that are intimately involved with the etiology of cancer. Pro-
jected cancer statistics for 2007 developed by the American 
Cancer Society clearly illustrate the effect of cancer on the 
population. It was estimated that in the United States, about 
1.44 million new cases of cancer would arise in 2007. Also, 
the American Cancer Society predicted there would be about 
559,650 cancer-related deaths in 2007, which corresponds to 
over 1,500 deaths per day [1]. These statistics, among many 
others, display the degree of this alarming problem and sug-
gest that more diagnostic, prognostic, and therapeutic inter-
ventions need to be developed in order to sufficiently offset 
the growing number of cancer-related deaths for the better-
ment of public health.  
  Normal cells in the human body incorporate several 
mechanisms that ensure proper cell division, differentiation, 
and apoptosis. Various regulatory factors control the expres-
sion of genes such as tumor suppressor genes and oncogenes, 
allowing for the timely and coordinated execution of these 
processes. In cancer, however, these genes do not function 
properly, causing these processes to become uncontrolled,   
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resulting in tumor formation [2]. Recent research has led to 
significant progress in terms of elucidating the molecular 
mechanisms and damaged genes involved in cancer. One 
such example is the discovery of microRNAs (miRNAs), 
leading to a sudden escalation in research implicating these 
tiny RNA molecules as integral players in cancer biology.  
  miRNAs were first discovered in 1993 while studying 
Caenorhabditis elegans. The first miRNA, lin-4, was charac-
terized as a small, non-coding RNA molecule that played a 
role in development by negatively regulating lin-14 expres-
sion [3, 4]. The second miRNA, let-7, was discovered in 
2000 in C. elegans [5]. The discovery of these two miRNAs 
stimulated a huge explosion in miRNA research. In the past 
six years, over 4500 miRNAs have been identified in verte-
brates, flies, worms, plants and viruses [6-8]. This number is 
likely to grow in the future because further innovative re-
search is continuing at a very rapid pace.  
miRNA BIOGENESIS 
  miRNA biogenesis (Fig. 1) begins with transcription by 
RNA polymerase II, yielding a primary miRNA (pri-
miRNA) which ranges anywhere from hundreds to thou-
sands of nucleotides in length [9]. Two steps, each accom-
plished by a different ribonuclease III (RNaseIII), are needed 
in order to yield a functional, mature miRNA. The two steps 
described below focus on humans. The first step is catalyzed 
by the nuclear RNaseIII, Drosha, which cleaves the pri-
miRNA to yield the precursor miRNA (pre-miRNA), about 
70 nucleotides in length. Drosha requires the help of the 
dsRBD protein, DGCR8, in order to ensure accurate and 
efficient processing of the pri-miRNA into the pre-miRNA  
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[10-15]. The nuclear export factor Exportin 5 binds the pre-
miRNA and transports it to the cytoplasm, where the second 
step in miRNA biogenesis takes place [16-18]. The second 
RNaseIII, Dicer, processes the pre-miRNA and yields an 
RNA duplex about 22 nucleotides in length. This enzyme 
needs the help of another dsRBD protein, the trans-activator 
RNA (tar)-binding protein (TRBP) [19-23]. One strand of 
this duplex is the mature miRNA which preferentially enters 
the RNA-induced silencing complex (RISC) [24-26], ena-
bling it to engage in its main duty, post-transcriptional regu-
lation of functional mRNA.  
MODES OF miRNA ACTION 
  The miRNAs play a role in post-transcriptional regula-
tion by binding to the 3’ untranslated region (3’UTR) of tar-
get messengerRNA (mRNA). Either perfect or near perfect 
complimentary base pairing results in the degradation of the 
mRNA, while partial base pairing leads to translational inhi-
bition and silencing of the targeted message [27-29]. It has 
been observed that plant miRNAs engage in the first mecha-
nism while animal miRNAs primarily employ the latter 
mechanism, tolerant of mismatches (Fig. 2). The imperfect 
miRNA-mRNA complementarity in human cells is usually 
composed of matched nucleotides in the 5’ portion of the 
miRNA, termed the seed sequence (positions 2-7), with 
mismatches at positions 10 and 11 [30-32]. In humans, this 
complex leads to the inhibition of target gene protein transla-
tion and only very rarely causes degradation of the mRNA 
[33]. Although this imperfect binding of human miRNAs is 
commonly accepted, there is still much debate regarding 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). miRNA Biogenesis. RNA polymerase II transcribes the miRNA gene and forms a pri-miRNA transcript, ranging anywhere from 
hundreds to thousands of nucleotides in length. This is processed by the RNase III Drosha and DGCR8, yielding the ~70 nucleotide pre-
miRNA. The pre-miRNA is transported to the cytoplasm via Exportin 5 where it is processed by the RNase III Dicer and TRBP, releasing a 
miRNA:miRNA* duplex, about 22 nucleotides in length. One strand of this duplex is degraded while the other strand, the mature miRNA, 
preferentially enters the RNA-induced silencing complex (RISC), allowing it to engage in post-transcriptional regulation of functional 
mRNAs. MicroRNA and Cancer  Current Genomics, 2008, Vol. 9, No. 2    99 
how the mi-RISC-mRNA complex actually triggers the si-
lencing of mRNA gene expression. The various propositions 
of this mechanism have recently been put forward as docu-
mented in recent review articles [34, 35].  
ROLES OF miRNA IN NORMAL PHYSIOLOGY AND 
PATHOLOGY 
  The miRNAs have been discovered and studied in a wide 
range of species which has allowed for cross-species com-
parisons yielding very important findings. These compari-
sons have shown that many miRNAs are conserved across 
animal species, indicating that they are fundamental aspects 
of normal biological processes. In fact, predictions of 
miRNA targets in various computer modeling studies have 
suggested that up to 30% of human protein coding genes 
may be regulated by miRNAs [33], making them one of the 
largest classes of regulatory molecules in humans. miRNAs 
have been implicated in a wide array of cell functions in both 
vertebrates and invertebrates, including processes integral to 
normal physiology such as cell proliferation, differentiation, 
death, stress resistance, and fat metabolism [6]. With respect 
to vertebrates, genetic knockouts in animals have been useful 
models to study miRNA function. For example, genetic re-
moval of the RNaseIII Dicer in zebrafish and mice has 
shown the vital roles of miRNAs that are essential in many 
cellular processes such as in the development of a species. 
An animal deficient in this important enzyme is unable to 
produce new miRNAs. The loss of Dicer caused lethality in 
both species, indicating that Dicer plays a vital modulatory 
role during development [36-39]. Other similar studies have 
displayed important roles of miRNAs in processes of stem 
cell differentiation, cardiac and skeletal muscle development, 
neurogenesis, hematopoiesis, and immune function [40-44]. 
Along with many normal processes, miRNAs or the process-
ing of miRNAs has been shown to be key players in several 
human diseases. Among the many, some include Spinal 
muscular atrophy, fragile X mental retardation, Parkinson’s 
disease, and DiGeorge syndrome [13, 45-47]. Recent re-
search has also identified the critical involvement of miR-
NAs in cancer, the main focus of this article.  
IMPLICATIONS OF miRNAs IN CANCER 
  Defects in normal cell processes such as differentiation, 
proliferation, and apoptosis are all well-known to be in-
volved in cancer pathogenesis. One reason the connection 
between miRNA and cancer was initially made is because 
miRNAs were found to be involved in many of these proc-
esses. This connection initiated research which further rein-
forced the correlation between miRNAs and cancer devel-
opment. Researchers discovered that there is aberrant 
miRNA expression when comparing various types of cancer 
with normal tissues. Although the association between 
miRNA and cancer was initially suggested, the question still 
remained regarding whether the altered miRNA expression 
was a cause or a consequence of cancer [33]. Also, not much 
was known about the specific targets and functions of miR-
NAs. The first direct evidence for the key role of miRNAs in 
cancer came from a study in human chronic lymphocytic 
leukemia (CLL). In this study, Calin et al. decided to focus 
on the deletion at locus 13q14, the most frequent chromoso-
mal abnormality in CLL. Although many studies had fo-
cused on this deletion, they all failed to notice consistent 
involvement of any of the genes located in the deletion lo-
cus. They further analyzed this region and found that genes 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Modes of miRNA Action. A: complimentary base pairing of miRNA with mRNA, which results in the degradation of mRNAs, a 
common mechanism in plants. B: imperfect base pairing of miRNA with mRNA results in translational inhibition, the typical mode of action 
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for two miRNAs, miR-15 and miR-16, were located exactly 
in the deleted region. Additional investigation of these two 
miRNAs revealed that they both showed a significant reduc-
tion in expression when compared to their normal tissue 
counterparts [48]. Although future research is needed to de-
termine their mechanism of action and their exact role in 
CLL, these findings suggest that these two miRNAs play a 
causal role in CLL. This study sparked significant miRNA 
research, leading to the discovery of exact targets and func-
tions of miRNAs in relation to cancer as well as clinical sig-
nificance involving the diagnostic, prognostic, and therapeu-
tic value of miRNAs.  
  Some miRNAs are thought to have oncogenic activity 
while others have tumor suppressor activity (Table 1). It is 
important to note that these distinctions may not be so strict 
and that some miRNAs may express either activity, depend-
ing on the situation and tissue type. Nevertheless, the major-
ity of recent research provides results that point toward one 
category or the other. It is also possible to group miRNAs 
based on their various functions (Table 2). Some play a sin-
gle role while others contribute to cancer through multiple 
cellular functions. Although there has been significant pro-
gress in regards to many miRNAs, only the most highly 
studied and well-described miRNAs in each category will be 
discussed below.  
miRNAs WITH ONCOGENIC ACTIVITY 
miR-17-92 Cluster 
  Oncogenic miRNAs are up-regulated in cancer and con-
tribute to its pathology through various mechanisms such as 
targeting tumor suppressor genes. Falling into this category 
is the group of six miRNAs termed the miR-17-92 cluster 
Table 1.  Various Oncogenic and Tumor Suppressor miRNAs 
miRNA  Tumor Suppressor Activity  Oncogenic Activity  Expression in Cancer  Some Targets 
Let-7 family     -  RAS,  PRDM1,  HMGA2 
miR-9    +  PRDM1 
miR-10a    +  Tsp1 
miR-15a/16-1     - BCL-2 
miR-17-5p     -  AIB1,  E2F1 
miR-17-92 cluster      +  Tsp1, CTGF, E2F1, AIB1, TGFBR2 
miR-21     +  PTEN, TPM1, Pdcd4, maspin 
miR-29b     -  MCL-1,  TCL-1 
miR-34a     - E2F3 
miR-106a    +  RB-1 
miR-124a     - CDK6 
miR-127     - BCL-6 
miR-141    +  CLOCK 
miR-142    +  c-myc 
miR-143      -  Raf1, G-protein 7, ERK5 
miR-145      -  Raf1, G-protein 7 
miR-146b    +  KIT 
miR-155/bic    +  AT1R,  TP53INP1 
miR-181b     - TCL-1 
miR-197    +  ACVR1,  TSPAN3 
miR-200b    +  PTPN12 
miR-221    +  KIT,  p27(Kip1) 
miR-222    +  KIT,  p27(Kip1) 
miR-346    +  EFEMP2 
miR-372    +  LATS2 
miR-373    +  LATS2 MicroRNA and Cancer  Current Genomics, 2008, Vol. 9, No. 2    101 
which is made up of miR-17, miR-18a, miR-19a, miR-20a, 
miR-19b-1, and miR-92-1 [49]. This cluster is encoded by 
the c13orf25 gene located at 13q31, a genomic locus that is 
frequently amplified in cases of B-cell lymphoma and other 
various tumor types. He et al. researched this further by 
comparing B-cell lymphoma samples and cell lines to nor-
mal B-cells [50]. The comparison displayed a high level of 
expression of the six mature miRNAs in the cancer cell lines, 
prompting the hypothesis that the miR-17-92 cluster may 
contribute to tumor development. These researchers tested 
this directly in a mouse model of B-cell lymphoma with 
some of the transgenic animals carrying the c-myc oncogene. 
After inducing expression of the miR-17-92 cluster, they 
noticed that animals expressing both c-myc and the miRNA 
cluster developed highly malignant, disseminated lympho-
mas capable of evading apoptosis [50]. Similarly, Dews et 
al. investigated the role of the miR-17-92 cluster in Myc-
induced tumorigenesis [51]. It is known that Myc enhances 
angiogenesis by down regulating anti-angiogenic throm-
bospondin-1 (Tsp1) and related proteins, such as connective 
tissue growth factor (CTGF). They sought to determine 
whether Myc-induced up-regulation of the miR-17-92 cluster 
is directly responsible for the down regulation of these anti-
angiogenic factors. Anti-sense 2’-O-methyl oligoribonucleo-
tides targeting the miRNAs from this cluster caused partial 
restoration of Tsp1 and CTGF expression. They also gener-
ated cells exhibiting over-expression of this cluster through 
transduction and found lower levels of the two proteins, es-
pecially for CTGF [51], suggesting that the effects of the 
miR-17-92 cluster are angiogenic and oncogenic.  
miR-155 
  Another miRNA that seems to fit into the oncogenic 
group is miR-155. The BIC gene, elevated in cancer, has 
been shown to produce non-protein coding RNA. Recently, 
in mice, miR-155 was found to be encoded within the phylo-
genetically conserved region of BIC RNA [52]. Therefore, 
Eis et al. hypothesized that miR-155 could be responsible for 
the oncogenic activity of BIC RNA and decided to investi-
gate it further. In clinical B-cell lymphomas they found that 
BIC RNA, and to an even greater extent miR-155, both had 
increased accumulation when compared to controls [53]. 
Furthermore, many studies using miRNA expression profil-
ing have recognized the altered expression of miR-155 in a 
variety of cancers when compared to their normal counter-
parts. For example, a study by Iorio et al. [54] analyzed 76 
breast cancer and 10 normal breast samples and compared 
their miRNA expression profiles in order to identify which 
miRNAs were significantly deregulated in breast cancer. The 
miR-155 was found to be ranked as one of the top five dif-
ferentially expressed miRNAs. It was consistently up-regu- 
lated, suggesting a potential oncogenic role in cancer [54]. 
Other studies have also recognized the up-regulation of miR-
155 in cancers [55-58].  
  Another study identified one of the specific targets of 
miR-155. Tumor protein 53-induced nuclear protein 1 
(TP53INP1) is a pro-apoptotic stress-induced p53 target 
gene. A study by Gironella et al. [59] showed that TP53INP1 
expression is significantly reduced in pancreatic ductal ade-
nocarcinoma (PDAC) and therefore, they decided to eluci-
date the molecular mechanism by which the expression is 
deregulated. Since they found that only protein levels are 
changed and not mRNA levels, they hypothesized that a 
post-transcriptional mechanism is responsible for regulating 
expression and that a miRNA may function as a key player 
in the regulation of TP53INP1. Bioinformatic approaches 
revealed miR-155 as a probable target. Therefore, in order to 
test this, they transfected Capan2 cells with an anti-miR-155 
oligonucleotide which caused re-expression of TP53INP1 
and a significant increase in apoptosis, demonstrating that 
TP53INP1 is a target of miR-155 [59].  
miR-21 
  An additional well-studied miRNA with oncogenic activ-
ity is miR-21. Similar to miR-155, this miRNA is deregu-
lated in a variety of cancers. In the same study by Iorio et al. 
as mentioned above, miR-21 also ranked as one of the top 
five differentially expressed miRNAs and was consistently 
Table 2.  Various miRNAs Grouped by Function 
Function miRNAs 
PRO: miR-10a, miR-17-92 cluster, miR-155/bic 
Angiogenesis 
ANTI: miR-34a 
PRO: miR-15a/16-1, miR-29b, miR-34a, miR-127 
Apoptosis 
ANTI: miR-17-92 cluster, miR-21, miR-155/bic, miR-221, miR-222 
PRO: miR-21, miR-197, miR-373 
Invasion/Metastasis 
ANTI: --- 
PRO: miR-17-92 cluster, miR-21, miR-141, miR-197, miR-221, miR-222, miR-346, miR-372, miR-373 
Proliferation 
ANTI: let-7 family, miR-16-1, miR-17-5p, miR-34a, miR-143, miR-145 
PRO: miR-17-92 cluster, miR-372, miR-373 
Tumorigenesis 
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up-regulated, suggesting an oncogenic role [54]. In a study 
by Chan et al., miRNA expression analysis of human 
glioblastoma tumor tissues, early-passage glioblastoma cul-
tures, and six established glioblastoma cell lines displayed 
strikingly elevated miR-21 levels when compared to controls 
[60]. To study the biological significance of this elevation, 
they utilized a loss-of-function approach in which they em-
ployed two different anti-sense oligonucleotide strategies, 
both of which produced similar results. In both cases, inhibi-
tion of miR-21 caused an increase in apoptosis due to activa-
tion of caspases, indicating the oncogenic role of this 
miRNA in cancer [60]. Si et al. found increased expression 
of miR-21 to be present in breast tumor tissues as well [61]. 
To test whether miR-21 may function as an oncogene, they 
used a knockdown approach using an anti-miR-21 inhibitor. 
The results showed inhibition of cell growth in vitro as well 
as inhibition of tumor growth in vivo in a xenograft carci-
noma mouse model after knockdown of miR-21. Finally, the 
use of anti-miR-21 displayed increased cell apoptosis, which 
was associated with down regulation of bcl-2 expression 
[61]. Further studies sought to elucidate exact targets of 
miR-21 as presented below. Pdcd4, a novel tumor suppres-
sor, is down regulated in various types of cancer, especially 
lung and colorectal, which is associated with poor patient 
prognosis. Since little was known about the regulatory 
mechanisms of Pdcd4 in cancer, Asangani et al. sought to 
determine the role, if any, of miRNAs in the regulation of 
this tumor suppressor as well as their role in invasion and 
intravasation [62]. They screened the 3’UTR of Pdcd4 in 
search of any complementarity to the seed sequences of 
known miRNAs and found an exact match target sequence 
for miR-21. It was also found that Pdcd4 is inversely corre-
lated with miR-21 levels in colorectal cancer cell lines as 
well as the resected tumor tissues of 22 colorectal cancer 
patients. Moreover, anti-miR-21 transfected cells exhibited 
increased Pdcd4 expression and reduced invasion and in-
travasation, while over-expression of miR-21 in these cells 
showed the opposite effect [62], suggesting that Pdcd4 is a 
target of miR-21.  
miRNAs WITH TUMOR SUPPRESSOR ACTIVITY 
miR-15 and miR-16 
  In contrast to the oncogenic miRNAs, other miRNAs are 
considered to have tumor suppressor activity and are down 
regulated in cancer. Along with the initial findings discussed 
earlier, research has further implicated miR-15 and miR-16 
as miRNAs with tumor suppressor activity. One study by 
Cimmino  et al. investigated the role of these miRNAs in 
relation to bcl-2, an anti-apoptotic player in survival path-
ways which has been found to be over-expressed in a variety 
of human cancers [63]. They found that the levels of miR-15 
and miR-16 are inversely correlated with bcl-2 expression in 
CLL cells. Also, they determined the effects of transfection 
of these miRNAs on bcl-2 expression. In a cell line with high 
bcl-2 and no expression of these miRNAs, they found that 
transfection of miR-15 and miR-16 caused a significant re-
duction in bcl-2 expression. Finally, they identified the bio-
logical effects of down regulating bcl-2 by miR-15 and miR-
16. They found that bcl-2 down regulation by these two 
miRNAs caused apoptosis in a CLL cell line [64].  
let-7 Family 
  One of the most studied miRNA groups with tumor sup-
pressor potential is the let-7 family. The let-7 family consists 
of let-7, miR-48, miR-84, and miR-241 [49]. Early research 
findings showed reduced let-7 expression in cancer and fur-
ther studies suggested the role and biological significance of 
let-7 in prognosis. Takamizawa et al. analyzed 20 human 
lung cancer cell lines as well as 16 primary human lung can-
cer tissues and noticed that the reduction in let-7 expression 
was a frequent occurrence when compared to controls [65]. 
Furthermore, they collected 143 lung cancer specimens from 
patients that had undergone curative resection and analyzed 
them using real-time reverse transcription-PCR. Unsuper-
vised hierarchical analysis classified the specimens into two 
groups, displaying significantly shorter post-operative sur-
vival in cases with reduced let-7 expression. Biological sig-
nificance of this reduction was also achieved by over-
expressing let-7f in the A549 lung adenocarcinoma cell line 
which resulted in a 78.6% reduction in the number of colo-
nies [65]. Similar to the other highly studied miRNAs, many 
miRNA expression studies have revealed reduced expression 
of the let-7 family in various types of cancer. Research has 
also determined exact targets of this tumor suppressing let-7 
family. Johnson et al. identified the regulation of let-60, the 
ortholog of the human RAS oncogene, by let-7 in C. elegans 
[66]. A computational screen indicated let-60 as one of the 
top scoring genes with let-7 family complementary sites in 
their 3’UTR. Consequently, they decided to extend these 
results to humans and have identified a potential relation-
ship. They found that all three human RAS 3’UTRs contain 
multiple let-7 family complementary sites, suggesting a pos-
sible regulatory role of these miRNAs. Additionally, trans-
fection of HepG2 cells with a let-7a precursor resulted in 
about 70% reduction of RAS. In contrast, transfection of 
HeLa cells with anti-sense let-7 molecules reduced the ex-
pression of let-7 and in turn, allowed for an approximately 
70% increase in RAS levels [66]. These results suggest a 
possible mechanism for let-7 in cancer development. Similar 
elucidation of let-7 targets have occurred in other studies, 
like the regulation of high-mobility group protein HMGA2 
by let-7 [67].  
Roles in the p53 Tumor Suppressor Network 
  Lastly, of important note is the role of miRNAs in the 
p53 tumor suppressor network. p53 is a tumor suppressor 
protein that coordinates cellular responses to various cancer 
initiating stressors [68, 69]. Since miRNAs often display 
aberrant expression in cancer, studies hypothesized that 
miRNAs may be targets of the p53 network in response to 
stress. In a study by Chang et al., the researchers treated cells 
with the DNA-damaging agent adriamycin and subsequently 
performed a custom microarray analysis [70]. Among the 
miRNAs up-regulated upon DNA damage, miR-34a had the 
largest magnitude of change. They then characterized the 
structure of the miR-34a primary transcript and promoter and 
found that it is directly transactivated by p53. Additionally, 
they found that increased expression of miR-34a resulted in 
increased apoptosis and also caused changes in the expres-
sion of genes related to many cellular processes such as cell-
cycle progression, apoptosis, DNA repair, and angiogenesis 
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portant role in controlling gene expression of the p53 tumor 
suppressor network components. Another study shows simi-
lar results [71] and others highlighted the importance of 
miRNAs like let-7 and miR-15/16 as important players in the 
p53 tumor suppressor network [72].  
miRNA AND THE CLINICAL CANCER 
Diagnostic Value 
  Now the question arises of how and to what extent miR-
NAs will be utilized and translated into the clinical setting. 
Recent research indicates that miRNAs will most likely have 
diagnostic, prognostic, and therapeutic value. Many studies 
have displayed that miRNA expression profiles can be used 
to differentiate different types of tissue. For example, one 
study by Lee et al. completed real-time PCR profiling of 
over 200 miRNA precursors in specimens of human pancre-
atic adenocarcinoma, paired benign tissue, normal pancreatic 
tissue, pancreatitis, and a variety of pancreatic cell lines. 
Hierarchical clustering was able to differentiate the tumor 
tissue from normal pancreatic tissue, pancreatitis, and cell 
lines. Also, using the prediction analysis of microarrays 
(PAM) algorithm, researchers determined whether or not 
miRNA expression data could successfully predict which 
class the samples fit in. PAM correctly classified all of the 
tested tumor samples and 11 of 15 of the tested benign sam-
ples [73]. Another study reported by Porkka et al. involved 
expression profiling of 319 miRNAs in 6 prostate cancer cell 
lines, 9 prostate cancer xenograft samples, and 13 clinical 
prostate tissue samples (4 benign prostatic hyperplasia, 5 
untreated prostate carcinomas, and 4 hormone-refractory 
prostate carcinomas). This was done in order to determine 
the prostate cancer miRNA expression profile and to use this 
information in classifying prostate tumors. They found dif-
ferential expression of 51 miRNAs between benign tumors 
and carcinoma tumors. Also, hierarchical clustering of the 
tumor samples successfully separated the carcinomas from 
the benign prostatic hyperplasia samples as well as further 
separated the carcinoma tumors according to their androgen 
dependence [74]. The studies described above provide evi-
dence for the potential use of miRNA expression profiling as 
a novel tool in cancer diagnosis.  
Prognostic Value 
  The miRNAs may also have significant value in terms of 
cancer prognosis. Various studies have been successful in 
correlating miRNA expression levels with survival time. 
Roldo  et al. used a custom microarray to determine the 
miRNA expression in 12 non-tumor pancreas samples and 
44 pancreatic primary tumors [75]. Not only did this data 
reveal the diagnostic value of miRNA expression patterns, 
they were also able to achieve prognostic value. This group 
found that the up-regulation of miR-21 is strongly associated 
with both a high Ki67 proliferation index and presence of 
liver metastasis [75]. A study by Bloomston et al. also dem-
onstrates the prognostic value of miRNAs [76]. This group 
obtained tissue samples from 65 patients who had undergone 
resection for PDAC as well as from 42 patients with chronic 
pancreatitis and tested the expression of miR-196a-2. The 
results displayed that miR-196a-2 significantly predicted 
duration of survival. High expression of this miRNA had a 
median survival of 14.3 months compared with a median of 
26.5 months for those with low expression [76]. These two 
studies, among many others, signify that miRNA expression 
profiling not only can be used in diagnosis, but can also be 
used as prognostic markers in cancer.  
Therapeutic Value 
  Utilization of miRNAs in therapy is an interesting idea 
and a major focus of current research activities. One poten-
tial strategy is inactivating oncogenic miRNAs. Various 
studies have employed 2’-O-methyl oligonucleotides [77, 
78] or locked nucleic acid-modified oligonucleotides [79] to 
block miRNA function. One such study by Meister et al. 
synthesized anti-miR-21 2’-O-methyl oligonucleotides and 
added them to HeLa extracts. It was found that using this 
anti-sense oligonucleotide significantly decreased the activ-
ity of miR-21 when compared to control oligonucleotides 
[78]. A similar study completed in mice suggests the poten-
tial of this strategy in vivo as well [80].  
  Another possible route to follow in terms of therapy is in 
the areas of restoring down regulated miRNAs that function 
as tumor suppressors. Johnson et al. focused on this concept 
in his study on elucidating the function of let-7 in human cell 
proliferation pathways [81]. As stated earlier, let-7 functions 
as a tumor suppressor and is poorly expressed or deleted in 
human tumors. In this study they over-expressed let-7 by 
using exogenously transfected pre-let-7 RNAs and deter-
mined the effect on lung and liver cancer cells. They found 
that over-expressing let-7 consistently reduced the number of 
proliferating cells in both cell lines [81]. This finding clearly 
suggests the possible effect of restoring tumor suppressor 
miRNAs in cancer therapy.  
  A third possible strategy is creating synthetic miRNAs to 
target mRNAs of genes known to contribute to cancer. A 
study by Tsuda et al. focused on the glioma-associated anti-
gen-1 (Gli-1) which plays a role in the sonic hedgehog sig-
naling cascade, a pathway implicated in the growth of a 
number of human malignancies [82]. Their objective was to 
determine whether or not synthetic miRNA targeting Gli-1 
mRNA could be used to inhibit tumor cell proliferation in 
ovarian SK-OV-3 and pancreatic MiaPaCa-2. They found 
that their designed synthetic miRNAs reduced expression of 
the Gli-1 protein and inhibited cell proliferation and division. 
They were able to induce a significant reduction in the num-
ber of tumor cells in two cell lines that express high levels of 
the Gli-1 protein [82].  
  Finally, a fourth possible strategy that has been proposed 
is utilizing miRNAs as agents to alter resistance to cytotoxic 
anti-cancer therapy. It has been known that tumor cells use 
pre-existing survival pathways to evade the cytotoxic effects 
of anti-cancer agents. A study by Weidhaas et al. sought to 
determine whether miRNAs play a role in this genetic re-
sponse [83]. They used the lung cancer cell line A549 and 
the normal lung epithelial cell line CLR2741 and compared 
the miRNA expression before and after irradiation using a 
microarray profile. It was found that each member of the let-
7 family, except for let-7g, decreased significantly by 2 
hours after irradiation in both cell lines. The let-7 family 
represented a large proportion of the altered miRNAs in re-
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the cancer cells and normal epithelial cells suggests a highly 
conserved global miRNA response. This also suggests that 
miRNAs are possibly integral aspects of the response to cy-
totoxic insult. Since the let-7 family result was so significant, 
they decided to determine the effect of altering its expression 
on the radiation response and cell survival. They were able to 
create a radiosensitive state in vitro in lung cancer cells and 
in vivo in a C. elegans model of radiation-induced cell death 
when they over-expressed the let-7 family of miRNAs. In 
contrast, decreasing the levels of the let-7 family caused ra-
dio-resistance [83]. This study and the others above all pro-
vide evidence for the potential use of miRNAs in various 
therapeutic strategies.  
CURRENT RESEARCH 
  Our laboratory has completed some preliminary experi-
ments that resulted in exciting data which reinforces many of 
the ideas discussed above and further suggest that cutting-
edge research in this area is urgently needed. First, we de-
cided to compare a normal pancreatic epithelial cell line 
(HPDE) with a pancreatic cancer cell line (Panc-1) in order 
to display the differential miRNA expression between the 
two. Total RNA was isolated from both cell lines using the 
mirVana™ miRNA Isolation Kit (Ambion Inc, TX). Upon 
successful isolation, total RNA samples were sent to 
LCSciences (Houston, TX) where they completed a dual 
sample miRNA microarray analysis. Results showed that 
121 miRNA transcripts were differentially expressed be-
tween the two cell lines (p < 0.01). Of these, 75 were up-
regulated and 46 were down regulated in Panc-1 when com-
pared to HPDE (Table 3). Some results did not perfectly 
match the existing literature, which could be partly due to 
the lack of comparing multiple cell lines and tissue samples. 
For example, our results show lower expression of miR-155 
in Panc-1 when compared to HPDE, even though most of the 
literature suggests this miRNA as being up-regulated in can-
cer and thus known as an oncogenic miRNA. In regards to 
the miRNAs that were shown to have either oncogenic or 
tumor suppressor activity in many experimental systems as 
shown in Table 1, our results also showed similar up-
regulation of the oncogenic miRNAs miR-10a and miR-146b 
as well as down regulation of the tumor suppressor miRNAs 
let-7a and let-7f in cancer when compared to the normal 
cells. Our results were further analyzed by the Bioinformat-
ics Core Facility at Wayne State University in order to de-
termine potential miRNA targets. For example, it was found 
that the oncogenic miR-10a may target and negatively regu-
late tyrosine kinase, non-receptor 1 (TNK1). This gene plays 
a role in the indirect suppression of Ras activity resulting in 
the inhibition of cell growth. Thus, negative regulation of 
this gene by miR-10a may counteract its effect and promote 
Ras activity and cell growth, supporting the suggested onco-
genic role of this miRNA in cancer. These results suggest 
that further in-depth investigations are needed using multiple 
cancer cell lines and tumors compared to normal cells and 
normal pancreas in order to firmly establish the role of spe-
cific miRNAs toward development of therapeutic strategies 
in the future.  
  Since these preliminary results showed aberrant miRNA 
expression when comparing the pancreatic cancer cell line to 
a normal pancreatic epithelial cell line, we decided to per-
form another study for assessing the effect of two chemopre-
ventive agents on miRNA expression. The pancreatic cancer 
cell lines Panc-1 and Colo-357 were treated with 25M B-
DIM (3,3’-diindilylmethane from BioResponse, Boulder, 
CO) or 25M G2535 (isoflavone mixture from Organic 
Technologies, Coshocton, OH). After the 72 hour treatment 
period, cells were subjected to total RNA isolation using the 
mirVana™ miRNA Isolation Kit (Ambion Inc, TX). Total 
RNA samples were once again sent to LCSciences (Houston, 
TX) where they completed miRNA microarrays for each 
sample. Only taking into account statistically significant data 
with high signals (signal > 500), the results showed that B-
DIM up-regulated 12 miRNA and down regulated 20 
miRNA in Panc-1 cells. G2535 increased expression of 19 
miRNA and inhibited expression of 28 miRNA in the same 
cell line (Table 4). In regards to Colo-357 cells, B-DIM up-
regulated 13 miRNA and down regulated 13 miRNA. G2535 
increased expression of 34 miRNA and inhibited expression 
of 22 miRNA in the same cell line (Table 5).  
 
Table  3.  Differential miRNA Expression when Comparing 
Panc-1 to HPDE
* 
Up-Regulated Down  Regulated 
Probe ID  Fold Diff.  Probe ID  Fold Diff. 
hsa-miR-369-3p 7.45  hsa-miR-205  9.63 
hsa-miR-376a 7.30 hsa-miR-200c 7.77 
hsa-miR-196a 7.30 hsa-miR-200b 7.68 
hsa-miR-493-5p 6.58  hsa-miR-224  7.04 
hsa-miR-368 6.52  hsa-miR-148a  5.59 
hsa-miR-495 5.93  hsa-miR-200a  5.57 
hsa-miR-10b 5.55 hsa-miR-584 5.23 
hsa-miR-10a 5.44 hsa-miR-575 5.05 
hsa-miR-409-3p 5.38  hsa-miR-801  4.86 
hsa-miR-432 5.28 hsa-miR-155 4.82 
hsa-miR-379 5.12 hsa-miR-452 4.35 
hsa-miR-487b 5.09 hsa-miR-141  4.30 
hsa-miR-494 4.80     
hsa-miR-127 4.78     
hsa-miR-382 4.66     
hsa-miR-299-5p 4.44     
hsa-miR-329 4.42     
hsa-miR-493-3p 4.20     
*Table only includes the miRNAs with at least a four fold difference in expression. 
 
  The treatments caused changes in miRNA expression that 
were once again mostly consistent with the known miRNA 
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our results were not consistent with the literature, most of 
our data was in direct agreement. For example, we found an 
increased expression of the oncogenic miR-21 in B-DIM 
treated Colo-357 which was unexpected, whereas most of 
the results displayed decreased expression of oncogenic 
miRNAs and increased expression of tumor suppressor 
miRNAs upon treatment with either agent, clearly supporting 
the role of B-DIM or G2535 as cancer preventing agents. It 
is possible that the up-regulation of miR-21 is due to a pre-
existing survival stress response. A similar explanation was 
previously documented by Rossi et al. to explain the increase 
in miR-21 expression in human colon cancer cells after ex-
posure to 5-fluorouracil in vitro [84]. miR-21 has been 
shown to have proliferative, metastatic, and anti-apoptotic 
 
Table 4.  Differential miRNA Expression After Treatment in 
Panc-1
* 
Up-Regulated Down  Regulated 
Probe ID  Fold Diff.  Probe ID  Fold Diff. 
B-DIM TREATMENT 
hsa-miR-663 1.97 hsa-miR-20b 0.82 
hsa-miR-638 1.46 hsa-miR-17  0.58 
hsa-miR-923 1.39  hsa-miR-106a  0.57 
hsa-miR-565 0.92 hsa-miR-93  0.55 
hsa-miR-30d 0.61 hsa-miR-221 0.55 
   hsa-miR-20a  0.54 
   hsa-miR-106b  0.45 
   hsa-miR-222  0.42 
G2535 TREATMENT 
hsa-miR-663 1.21  hsa-miR-34c-3p  2.37 
hsa-miR-374b 0.96 hsa-miR-376a 1.04 
hsa-miR-923 0.95  hsa-miR-196a  0.99 
hsa-miR-638 0.94 hsa-miR-320 0.81 
hsa-miR-30b 0.87 hsa-miR-99b 0.55 
hsa-miR-365 0.74  hsa-miR-127-3p  0.51 
hsa-miR-183 0.70 hsa-miR-382 0.49 
hsa-miR-30d 0.59 hsa-miR-20b 0.48 
hsa-miR-15b 0.54 hsa-miR-494 0.47 
hsa-miR-30a 0.54  hsa-miR-106b  0.46 
hsa-miR-425 0.53 hsa-miR-27b 0.46 
hsa-miR-30c 0.48 hsa-miR-23a 0.45 
hsa-let-7d 0.48  hsa-miR-93  0.41 
hsa-let-7f 0.47     
*Table only includes miRNAs with at least a .4 fold difference in expression. 
functions in cancer by targeting genes such as PTEN, TPM1, 
Pdcd4, and maspin. The drug-induced up-regulation of this 
 
Table 5.  Differential miRNA Expression After Treatment in 
Colo-357
* 
Up-Regulated Down  Regulated 
Probe ID  Fold Diff.  Probe ID  Fold Diff. 
B-DIM TREATMENT 
hsa-miR-146a 0.71  hsa-miR-654-5p  1.67 
hsa-miR-768-5p 0.62 hsa-miR-34c-3p 0.97 
hsa-miR-27b 0.61 hsa-miR-19b 0.79 
hsa-miR-26b 0.54 hsa-miR-663 0.65 
hsa-miR-27a 0.47 hsa-miR-565 0.64 
hsa-miR-125b 0.46 hsa-miR-638  0.60 
hsa-miR-148a 0.43 hsa-miR-205 0.50 
   hsa-miR-106a  0.40 
G2535 TREATMENT 
hsa-miR-146a 1.68  hsa-miR-654-5p  2.94 
hsa-miR-148a 1.39  hsa-miR-34c-3p  1.83 
hsa-miR-374b 1.26 hsa-miR-663  1.67 
hsa-miR-425 1.20 hsa-miR-19b 1.61 
hsa-miR-191 0.99 hsa-miR-923 1.05 
hsa-miR-768-5p 0.86  hsa-miR-20b  1.02 
hsa-miR-182 0.84 hsa-miR-638 0.91 
hsa-miR-128a 0.75 hsa-miR-106a 0.83 
hsa-miR-361-5p 0.74  hsa-miR-221  0.81 
hsa-miR-100 0.73 hsa-miR-565 0.72 
hsa-miR-151-5p 0.64  hsa-miR-17  0.69 
hsa-miR-15b 0.58 hsa-miR-149 0.68 
hsa-miR-423-5p 0.58  hsa-miR-200b  0.55 
hsa-miR-185 0.57 hsa-miR-205 0.54 
hsa-let-7d 0.49  hsa-miR-98  0.49 
hsa-miR-130b 0.47 hsa-miR-27b  0.47 
hsa-miR-30d 0.47 hsa-miR-20a 0.44 
hsa-miR-181a 0.46     
hsa-let-7b 0.44     
hsa-miR-200c 0.41     
hsa-let-7f 0.40     
hsa-miR-29a 0.40     
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miRNA could have been due to an intrinsic cellular response 
aimed at utilizing its functions to evade the cytotoxic effects 
of this anti-cancer agent. Building on this concept, it is also 
possible that down regulating this miRNA would chemosen-
sitize the cells and make them more susceptible to the anti-
cancer effects of these drugs. Thus, further research is 
needed to investigate the role of miR-21 and other miRNAs 
in survival pathways and to discern the potential for exploit-
ing these pathways for the development of a targeted ap-
proach for chemosensitization.  
  Upon treatment of Panc-1 with B-DIM, the oncogenic 
miRNAs miR-17, miR-20a, miR-106a, miR-221, and miR-
222 all showed decreased expression. Treatment of Panc-1 
with G2535 elicited decreased expression of the oncogenic 
miRNAs miR-17, miR-20a, miR-106a, miR-222 and in-
creased expression of the tumor suppressor miRNAs let-7a, 
let-7d, let-7e and let-7f. In regards to Colo-357, treatment 
with B-DIM showed decreased expression of the oncogenic 
miRNAs miR-17, miR-19b-1, miR-20a and miR-106a. Upon 
treatment of Colo-357 with G2535, the oncogenic miRNAs 
miR-17, miR-19b-1, miR-20a, miR-106a, miR-200b and 
miR-221 showed decreased expression and the tumor sup-
pressor miRNAs let-7a, let-7b, let-7c, let-7d, let-7f, let-7i 
and miR-16-1 showed increased expression. Once again, it is 
important to note that our results are consistent especially 
when compared to the results reported in Table 1. Other im-
portant miRNAs were also up-regulated and down regulated 
after treatment that are not mentioned in Table 1, suggesting 
that further in-depth research in this area is urgently needed, 
which is likely to assist in pursuing newer avenues for the 
treatment of pancreatic and other cancers using non-toxic 
natural products alone or in combination with conventional 
therapeutics.  
  It was also interesting when we examined the differences 
between B-DIM treatment and G2535 treatment. In both cell 
lines, treatment with G2535 caused a larger number of miR-
NAs that were significantly changed when compared to B-
DIM treatment. It is also noteworthy that B-DIM treatment 
affected mostly oncogenic miRNAs while G2535 treatment 
affected both oncogenic miRNAs as well as tumor suppres-
sor miRNAs, mostly members of the let-7 family, suggesting 
that these changes could reflect different mechanisms of ac-
tion between these two anti-cancer agents.  
  The Bioinformatics Core Facility at Wayne State Univer-
sity further analyzed this data in order to determine potential 
targets of the miRNAs that exhibited differential expression 
upon treatment. Due to the considerable number of potential 
targets for the miRNAs, we will limit our discussion by only 
focusing on miR-19b-1 of the miR-17-92 cluster as well as 
miR-221. Our analysis illustrated some potential targets that 
are consistent with the known targets as presented in Table 
1. For example, our analysis showed that miR-19b-1 may 
regulate the experimentally validated target Tsp1. It is also 
noted in Table 1 that the miR-17-92 cluster targets E2F1, a 
member of the E2F transcription factor family. We also 
found that miR-19b-1 may target E2F8, another related 
member of this transcription factor family which plays a role 
in inhibiting cellular proliferation. Thus miR-19b-1 may 
negatively regulate this transcription factor and allow prolif-
eration to occur, contributing to the oncogenic role of the 
miR-17-92 cluster in cancer. Other potential miRNA targets 
found in our analysis provided support for the various func-
tions of miRNAs as presented in Table 2. This table identi-
fies the miR-17-92 cluster which plays important roles in 
angiogenesis, apoptosis, proliferation, and tumorigenesis. 
Moreover, it is known that the various potential targets play 
significant roles in many of the same functions. For example, 
the targets Tsp1 and E2F8 mentioned above provide support 
for the angiogenic and proliferative functions of the miR-17-
92 cluster in cancer, respectively. Additionally, it was re-
ported that miR-19b-1 may also target caspase 8 (CASP8), 
death-associated protein kinase 3 (DAPK3), and pro-
grammed cell death 1 ligand 2 (PDCD1LG2), all genes 
known to be involved in apoptosis, further suggesting the 
anti-apoptotic function of the miR-17-92 cluster in cancer.  
  The oncogenic miR-221 has been suggested to play an 
important role in apoptosis and proliferation and thus, vari-
ous predicted targets were found to be involved in these 
processes. For example, our results showed that miR-221 
may target BCL6 co-repressor (BCOR), BCL2-like 14 
(apoptosis facilitator; BCL2L14), and programmed cell 
death 10 (PDCD10), all important genes that are known to 
regulate apoptosis. Negative regulation of these genes may 
impede their effects, suggesting the anti-apoptotic function 
of miR-221 in cancer. It was also found that miR-221 may 
target the WNT1 inducible signaling pathway protein 3 
(WISP3) which is a tumor suppressor that has been shown to 
have inhibitory effects on cell proliferation and angiogenesis. 
Thus, negative regulation by miR-221 may counteract this 
tumor suppressor and allow these oncogenic processes to 
occur, supporting its suggested proliferative role in cancer.  
  Overall, both B-DIM and G2535 are inhibitors of cancer 
cell growth and our preliminary results clearly suggest that 
these agents may execute their effects through pleiotropic 
mechanisms, especially involving the regulation of miRNAs. 
Decreased expression of oncogenic miRNAs upon treatment 
would most likely allow increased translation of their poten-
tial targets and cause induction of important cellular proc-
esses like apoptosis and inhibition of cell proliferation and 
angiogenesis. Conversely, increased expression of tumor 
suppressor miRNAs would most likely affect cellular proc-
esses in a similar manner, adding to the anti-cancer effects of 
these agents. Although these preliminary results are interest-
ing, further investigations are needed to elucidate the roles of 
many of these miRNAs that could be mechanistically linked 
in mediating the effects of B-DIM and G2535 in cancer pre-
vention and treatment in the future.  
CONCLUSION 
  Since the discovery in 1993, miRNAs have been impli-
cated as integral players in the biology of normal cells as 
well as diseased processes. Research over the last few years 
has allowed for the identification of various mechanisms and 
targets involving miRNAs, significantly improving our 
knowledge of cancer biology. Additionally, it has been de-
termined that miRNAs may be extended to the clinic due to 
their potential value in diagnosis, prognosis, and therapy. 
Although this realm of research is very promising, it is im-
portant to remember that it does not come without obstacles. 
For example, off-target effects may potentially hinder the MicroRNA and Cancer  Current Genomics, 2008, Vol. 9, No. 2    107 
efficacy of therapy involving miRNAs [85]. Further research 
will most likely solve these types of problems and also iden-
tify more functional roles of miRNAs that could be exploited 
for cancer prevention and therapy. Finally, we believe that 
the future holds a great promise for the miRNA revolution in 
the fight against cancer and other health problems.  
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ABBREVIATIONS 
miRNA =  MicroRNA 
3’UTR  =  3’ Untranslated region 
mRNA =  messengerRNA 
pri-miRNA = Primary  miRNA 
RNaseIII =  Ribonuclease  III 
pre-miRNA =  Precursor  miRNA 
TRBP =  Trans-activator RNA (tar)-binding protein 
RISC  =  RNA-induced silencing complex 
CLL =  Chronic  lymphocytic  leukemia 
Tsp1 =  Thrombospondin-1 
CTGF  =  Connective tissue growth factor 
TP53INP1  =  Tumor protein 53-induced nuclear protein 1 
PDAC =  Pancreatic  ductal  adenocarcinoma 
PAM  =  Prediction analysis of microarrays 
Gli-1 =  Glioma-associated  antigen-1 
REFERENCES 
[1]  Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Thun, M.J. 
Cancer statistics 2007. CA Cancer J. Clin. 2007, 57: 43-66.  
[2]  Esquela-Kerscher, A., Slack, F.J. Oncomirs - microRNAs with a 
role in cancer. Nat. Rev. Cancer 2006, 6: 259-269.  
[3]  Lee, R.C., Feinbaum, R.L., Ambros, V. The C. elegans hetero-
chronic gene lin-4 encodes small RNAs with antisense complemen-
tarity to lin-14. Cell 1993, 75: 843-854.  
[4]  Wightman, B., Ha, I., Ruvkun, G. Posttranscriptional regulation of 
the heterochronic gene lin-14 by lin-4 mediates temporal pattern 
formation in C. elegans. Cell 1993, 75: 855-862.  
[5]  Reinhart, B.J., Slack, F.J., Basson, M., Pasquinelli, A.E., Bettinger, 
J.C., Rougvie, A.E., Horvitz, H.R., Ruvkun, G. The 21-nucleotide 
let-7 RNA regulates developmental timing in Caenorhabditis ele-
gans. Nature 2000, 403: 901-906.  
[6]  Ambros, V. MicroRNA pathways in flies and worms: growth, 
death, fat, stress, and timing. Cell 2003, 113: 673-676.  
[7]  Bartel, D.P. MicroRNAs: genomics, biogenesis, mechanism, and 
function. Cell 2004, 116: 281-297.  
[8]  Griffiths-Jones, S., Grocock, R.J., van, D.S., Bateman, A., Enright, 
A.J. miRBase: microRNA sequences, targets and gene nomencla-
ture. Nucleic Acids Res. 2006, 34: D140-D144.  
[9]  Lee, Y., Kim, M., Han, J., Yeom, K.H., Lee, S., Baek, S.H., Kim, 
V.N. MicroRNA genes are transcribed by RNA polymerase II. 
EMBO J. 2004, 23: 4051-4060.  
[10]  Denli, A.M., Tops, B.B., Plasterk, R.H., Ketting, R.F., Hannon, 
G.J. Processing of primary microRNAs by the Microprocessor 
complex. Nature 2004, 432: 231-235.  
[11]  Gregory, R.I., Yan, K.P., Amuthan, G., Chendrimada, T., Dorato-
taj, B., Cooch, N., Shiekhattar, R. The Microprocessor complex 
mediates the genesis of microRNAs. Nature 2004, 432: 235-240.  
[12]  Han, J., Lee, Y., Yeom, K.H., Kim, Y.K., Jin, H., Kim, V.N. The 
Drosha-DGCR8 complex in primary microRNA processing. Genes 
Dev. 2004, 18: 3016-3027.  
[13]  Landthaler, M., Yalcin, A., Tuschl, T. The human DiGeorge syn-
drome critical region gene 8 and Its D. melanogaster homolog are 
required for miRNA biogenesis. Curr. Biol. 2004, 14: 2162-2167.  
[14]  Lee, Y., Jeon, K., Lee, J.T., Kim, S., Kim, V.N. MicroRNA matu-
ration: stepwise processing and subcellular localization. EMBO J. 
2002, 21: 4663-4670.  
[15]  Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., Lee, J., Pro-
vost, P., Radmark, O., Kim, S., Kim, V.N. The nuclear RNase III 
Drosha initiates microRNA processing. Nature 2003, 425: 415-419.  
[16]  Bohnsack, M.T., Czaplinski, K., Gorlich, D. Exportin 5 is a 
RanGTP-dependent dsRNA-binding protein that mediates nuclear 
export of pre-miRNAs. RNA 2004, 10: 185-191.  
[17]  Lund, E., Guttinger, S., Calado, A., Dahlberg, J.E., Kutay, U. Nu-
clear export of microRNA precursors. Science 2004, 303: 95-98.  
[18]  Yi, R., Qin, Y., Macara, I.G., Cullen,B.R. Exportin-5 mediates the 
nuclear export of pre-microRNAs and short hairpin RNAs. Genes 
Dev. 2003, 17: 3011-3016.  
[19]  Bernstein, E., Caudy, A.A., Hammond, S.M., Hannon, G.J. Role 
for a bidentate ribonuclease in the initiation step of RNA interfer-
ence. Nature 2001, 409: 363-366.  
[20]  Chendrimada, T.P., Gregory, R.I., Kumaraswamy, E., Norman, J., 
Cooch, N., Nishikura, K., Shiekhattar, R. TRBP recruits the Dicer 
complex to Ago2 for microRNA processing and gene silencing. 
Nature 2005, 436: 740-744.  
[21]  Grishok, A., Pasquinelli, A.E., Conte, D., Li, N., Parrish, S., Ha, I., 
Baillie, D.L., Fire, A., Ruvkun, G., Mello, C.C. Genes and mecha-
nisms related to RNA interference regulate expression of the small 
temporal RNAs that control C. elegans developmental timing. Cell 
2001, 106: 23-34.  
[22]  Hutvagner, G., McLachlan, J., Pasquinelli, A.E., Balint, E., Tuschl, 
T., Zamore, P.D. A cellular function for the RNA-interference en-
zyme Dicer in the maturation of the let-7 small temporal RNA. Sci-
ence 2001, 293: 834-838.  
[23]  Ketting, R.F., Fischer, S.E., Bernstein, E., Sijen, T., Hannon, G.J., 
Plasterk, R.H. Dicer functions in RNA interference and in synthesis 
of small RNA involved in developmental timing in C. elegans. 
Genes Dev. 2001, 15: 2654-2659.  
[24]  Hammond, S.M., Bernstein, E., Beach, D., Hannon, G.J. An RNA-
directed nuclease mediates post-transcriptional gene silencing in 
Drosophila cells. Nature 2000, 404: 293-296.  
[25]  Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R., Tuschl, 
T. Single-stranded antisense siRNAs guide target RNA cleavage in 
RNAi. Cell 2002, 110: 563-574.  
[26]  Schwarz, D.S., Hutvagner, G., Haley, B., Zamore, P.D. Evidence 
that siRNAs function as guides, not primers, in the Drosophila and 
human RNAi pathways. Mol. Cell 2002, 10: 537-548.  
[27]  Liu, J., Valencia-Sanchez, M.A., Hannon, G.J., Parker, R. Mi-
croRNA-dependent localization of targeted mRNAs to mammalian 
P-bodies. Nat. Cell Biol. 2005, 7: 719-723.  
[28]  Saxena, S., Jonsson, Z.O., Dutta, A. Small RNAs with imperfect 
match to endogenous mRNA repress translation. Implications for 
off-target activity of small inhibitory RNA in mammalian cells. J. 
Biol. Chem. 2003, 278: 44312-44319.  
[29]  Sen, G.L., Blau, H.M. Argonaute 2/RISC resides in sites of mam-
malian mRNA decay known as cytoplasmic bodies. Nat. Cell Biol. 
2005, 7: 633-636.  
[30]  Berkhout, B., Jeang, K.T. RISCy business: MicroRNAs, patho-
genesis, and viruses. J. Biol. Chem. 2007, 282: 26641-26645.  
[31]  Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., 
Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interfer-
ence in cultured mammalian cells. Nature 2001, 411: 494-498.  
[32]  Lewis, B.P., Burge, C.B., Bartel, D.P. Conserved seed pairing, 
often flanked by adenosines, indicates that thousands of human 
genes are microRNA targets. Cell 2005, 120: 15-20.  108    Current Genomics, 2008, Vol. 9, No. 2  VandenBoom II et al. 
[33]  Sassen, S., Miska, E.A., Caldas, C. MicroRNA-implications for 
cancer. Virchows Arch. 2008, 452(1): 1-10. 
[34]  Jackson, R.J., Standart, N. How do microRNAs regulate gene ex-
pression? Sci. STKE 2007, 2007: re1.  
[35]  Pillai, R.S., Bhattacharyya, S.N., Filipowicz, W. Repression of 
protein synthesis by miRNAs: how many mechanisms? Trends Cell 
Biol. 2007, 17: 118-126.  
[36]  Giraldez, A.J., Cinalli, R.M., Glasner, M.E., Enright, A.J., Thom-
son, J.M., Baskerville, S., Hammond, S.M., Bartel, D.P., Schier, 
A.F. MicroRNAs regulate brain morphogenesis in zebrafish. Sci-
ence 2005, 308: 833-838.  
[37]  Kanellopoulou, C., Muljo, S.A., Kung, A.L., Ganesan, S., Drapkin, 
R., Jenuwein, T., Livingston, D.M., Rajewsky, K. Dicer-deficient 
mouse embryonic stem cells are defective in differentiation and 
centromeric silencing. Genes Dev. 2005, 19: 489-501.  
[38]  Murchison, E.P., Partridge, J.F., Tam, O.H., Cheloufi, S., Hannon, 
G.J. Characterization of Dicer-deficient murine embryonic stem 
cells. Proc. Natl. Acad. Sci. USA 2005, 102: 12135-12140.  
[39]  Yang, W.J., Yang, D.D., Na, S., Sandusky, G.E., Zhang, Q., Zhao, 
G. Dicer is required for embryonic angiogenesis during mouse de-
velopment. J. Biol. Chem. 2005, 280: 9330-9335.  
[40]  Chen, C.Z., Li, L., Lodish, H.F., Bartel, D.P. MicroRNAs modulate 
hematopoietic lineage differentiation. Science 2004, 303: 83-86.  
[41]  Hatfield, S., Ruohola-Baker, H. microRNA and stem cell function. 
Cell Tissue Res. 2008, 331: 57-66.  
[42]  Krichevsky, A.M., Sonntag, K.C., Isacson, O., Kosik, K.S. Specific 
microRNAs modulate embryonic stem cell-derived neurogenesis. 
Stem Cells 2006, 24: 857-864.  
[43]  Vigorito, E., Perks, K.L., breu-Goodger, C., Bunting, S., Xiang, Z., 
Kohlhaas, S., Das, P.P., Miska, E.A., Rodriguez, A., Bradley, A., 
Smith, K.G., Rada,C., Enright, A.J., Toellner, K.M., Maclennan, 
I.C., Turner, M. microRNA-155 Regulates the Generation of Im-
munoglobulin Class-Switched Plasma Cells. Immunity  2007,  27: 
847-859.  
[44]  Zhao, Y., Ransom, J.F., Li, A., Vedantham, V., von, D.M., Muth, 
A.N., Tsuchihashi, T., McManus, M.T., Schwartz, R.J., Srivastava, 
D. Dysregulation of cardiogenesis, cardiac conduction, and cell cy-
cle in mice lacking miRNA-1-2. Cell 2007, 129: 303-317.  
[45]  Kim, J., Inoue, K., Ishii, J., Vanti, W.B., Voronov, S.V., Mur-
chison, E., Hannon, G., Abeliovich, A. A MicroRNA feedback cir-
cuit in midbrain dopamine neurons. Science 2007, 317: 1220-1224.  
[46]  Lin, S.L., Chang, S.J., Ying, S.Y. First in vivo evidence of mi-
croRNA-induced fragile X mental retardation syndrome. Mol. Psy-
chiatry 2006, 11: 616-617.  
[47]  Mourelatos, Z., Dostie, J., Paushkin, S., Sharma, A., Charroux, B., 
Abel, L., Rappsilber, J., Mann, M., Dreyfuss, G. miRNPs: a novel 
class of ribonucleoproteins containing numerous microRNAs. 
Genes Dev. 2002, 16: 720-728.  
[48]  Calin, G.A., Dumitru, C.D., Shimizu, M., Bichi, R., Zupo, S., 
Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., Rassenti, L., 
Kipps, T., Negrini, M., Bullrich, F., Croce, C.M. Frequent deletions 
and down-regulation of micro- RNA genes miR15 and miR16 at 
13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. 
USA 2002, 99: 15524-15529.  
[49]  Wiemer, E.A. The role of microRNAs in cancer: no small matter. 
Eur. J. Cancer 2007, 43: 1529-1544.  
[50]  He, L., Thomson, J.M., Hemann, M.T., Hernando-Monge, E., Mu, 
D., Goodson, S., Powers, S., Cordon-Cardo, C., Lowe, S.W., Han-
non, G.J., Hammond, S.M. A microRNA polycistron as a potential 
human oncogene. Nature 2005, 435: 828-833.  
[51]  Dews, M., Homayouni, A., Yu, D., Murphy, D., Sevignani, C., 
Wentzel, E., Furth, E.E., Lee, W.M., Enders, G.H., Mendell, J.T., 
Thomas-Tikhonenko, A. Augmentation of tumor angiogenesis by a 
Myc-activated microRNA cluster. Nat. Genet.  2006,  38: 1060-
1065.  
[52]  Tam, W. Identification and characterization of human BIC, a gene 
on chromosome 21 that encodes a noncoding RNA. Gene 2001, 
274: 157-167.  
[53]  Eis, P.S., Tam, W., Sun, L., Chadburn, A., Li, Z., Gomez, M.F., 
Lund, E., Dahlberg, J.E. Accumulation of miR-155 and BIC RNA 
in human B cell lymphomas. Proc. Natl. Acad. Sci. USA 2005, 102: 
3627-3632.  
[54]  Iorio, M.V., Ferracin, M., Liu, C.G., Veronese, A., Spizzo, R., 
Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., 
Menard, S., Palazzo, J.P., Rosenberg, A., Musiani, P., Volinia, S., 
Nenci, I., Calin, G.A., Querzoli, P., Negrini, M., Croce, C.M. Mi-
croRNA gene expression deregulation in human breast cancer. 
Cancer Res. 2005, 65: 7065-7070.  
[55]  Fulci, V., Chiaretti, S., Goldoni, M., Azzalin, G., Carucci, N., Ta-
volaro, S., Castellano, L., Magrelli, A., Citarella, F., Messina, M., 
Maggio, R., Peragine, N., Santangelo, S., Mauro, F.R., Landgraf, 
P., Tuschl, T., Weir, D.B., Chien, M., Russo, J.J., Ju, J., Sheridan, 
R., Sander, C., Zavolan, M., Guarini, A., Foa, R., Macino, G. 
Quantitative technologies establish a novel microRNA profile of 
chronic lymphocytic leukemia. Blood 2007, 109: 4944-4951.  
[56]  Lawrie, C.H., Soneji, S., Marafioti, T., Cooper, C.D., Palazzo, S., 
Paterson, J.C., Cattan, H., Enver, T., Mager, R., Boultwood, J., 
Wainscoat, J.S., Hatton, C.S. MicroRNA expression distinguishes 
between germinal center B cell-like and activated B cell-like sub-
types of diffuse large B cell lymphoma. Int. J. Cancer 2007, 121: 
1156-1161.  
[57]  Marton, S., Garcia, M.R., Robello, C., Persson, H., Trajtenberg, F., 
Pritsch, O., Rovira, C., Naya, H., Dighiero, G., Cayota, A. Small 
RNAs analysis in CLL reveals a deregulation of miRNA expres-
sion and novel miRNA candidates of putative relevance in CLL 
pathogenesis. Leukemia 2008, 22(2): 330-8. 
[58]  Volinia, S., Calin, G.A., Liu, C.G., Ambs, S., Cimmino, A., Pet-
rocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., Prueitt, 
R.L., Yanaihara, N., Lanza, G., Scarpa, A., Vecchione, A., Negrini, 
M., Harris, C.C., Croce, C.M. A microRNA expression signature of 
human solid tumors defines cancer gene targets. Proc. Natl. Acad. 
Sci. USA 2006, 103: 2257-2261.  
[59]  Gironella, M., Seux, M., Xie, M.J., Cano, C., Tomasini, R., Gom-
meaux, J., Garcia, S., Nowak, J., Yeung, M.L., Jeang, K.T., Chaix, 
A., Fazli, L., Motoo, Y., Wang, Q., Rocchi, P., Russo, A., Gleave, 
M., Dagorn, J.C., Iovanna, J.L., Carrier, A., Pebusque, M.J., 
Dusetti, N.J. Tumor protein 53-induced nuclear protein 1 expres-
sion is repressed by miR-155, and its restoration inhibits pancreatic 
tumor development. Proc. Natl. Acad. Sci. USA 2007, 104: 16170-
16175.  
[60]  Chan, J.A., Krichevsky, A.M., Kosik, K.S. MicroRNA-21 is an 
antiapoptotic factor in human glioblastoma cells. Cancer Res. 
2005, 65: 6029-6033.  
[61]  Si, M.L., Zhu, S., Wu, H., Lu, Z., Wu, F., Mo, Y.Y. miR-21-
mediated tumor growth. Oncogene 2007, 26: 2799-2803.  
[62]  Asangani, I.A., Rasheed, S.A., Nikolova, D.A., Leupold, J.H., 
Colburn, N.H., Post, S., Allgayer, H. MicroRNA-21 (miR-21) post-
transcriptionally downregulates tumor suppressor Pdcd4 and stimu-
lates invasion, intravasation and metastasis in colorectal cancer. 
Oncogene 2007, Oct. 29, [Epub ahead of print]. 
[63]  Sanchez-Beato, M., Sanchez-Aguilera, A., Piris, M.A. Cell cycle 
deregulation in B-cell lymphomas. Blood 2003, 101: 1220-1235.  
[64]  Cimmino, A., Calin, G.A., Fabbri, M., Iorio, M.V., Ferracin, M., 
Shimizu, M., Wojcik, S.E., Aqeilan, R.I., Zupo, S., Dono, M., Ras-
senti, L., Alder, H., Volinia, S., Liu, C.G., Kipps, T.J., Negrini, M., 
Croce, C.M. miR-15 and miR-16 induce apoptosis by targeting 
BCL2. Proc. Natl. Acad. Sci. USA 2005, 102: 13944-13949.  
[65]  Takamizawa, J., Konishi, H., Yanagisawa, K., Tomida, S., Osada, 
H., Endoh, H., Harano, T., Yatabe, Y., Nagino, M., Nimura, Y., 
Mitsudomi, T., Takahashi, T. Reduced expression of the let-7 mi-
croRNAs in human lung cancers in association with shortened 
postoperative survival. Cancer Res. 2004, 64: 3753-3756.  
[66]  Johnson, S.M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., 
Cheng, A., Labourier, E., Reinert, K.L., Brown, D., Slack, F.J. 
RAS is regulated by the let-7 microRNA family. Cell 2005, 120: 
635-647.  
[67]  Lee, Y.S., Dutta, A. The tumor suppressor microRNA let-7 re-
presses the HMGA2 oncogene. Genes Dev. 2007, 21: 1025-1030.  
[68]  Giono, L.E., Manfredi, J.J. The p53 tumor suppressor participates 
in multiple cell cycle checkpoints. J. Cell Physiol. 2006, 209: 13-
20.  
[69]  Vogelstein, B., Lane, D., Levine, A.J. Surfing the p53 network. 
Nature 2000, 408: 307-310.  
[70]  Chang, T.C., Wentzel, E.A., Kent, O.A., Ramachandran, K., Mul-
lendore, M., Lee, K.H., Feldmann, G., Yamakuchi, M., Ferlito, M., 
Lowenstein, C.J., Arking, D.E., Beer, M.A., Maitra, A., Mendell, 
J.T. Transactivation of miR-34a by p53 broadly influences gene 
expression and promotes apoptosis. Mol. Cell 2007, 26: 745-752.  
[71]  Corney, D.C., Flesken-Nikitin, A., Godwin, A.K., Wang, W., Ni-
kitin, A.Y. MicroRNA-34b and MicroRNA-34c are targets of p53 
and cooperate in control of cell proliferation and adhesion-
independent growth. Cancer Res. 2007, 67: 8433-8438.  MicroRNA and Cancer  Current Genomics, 2008, Vol. 9, No. 2    109 
[72]  Tarasov, V., Jung, P., Verdoodt, B., Lodygin, D., Epanchintsev, A., 
Menssen, A., Meister, G., Hermeking, H. Differential regulation of 
microRNAs by p53 revealed by massively parallel sequencing: 
miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell 
Cycle 2007, 6: 1586-1593.  
[73]  Lee, E.J., Gusev, Y., Jiang, J., Nuovo, G.J., Lerner, M.R., Frankel, 
W.L., Morgan, D.L., Postier, R.G., Brackett, D.J., Schmittgen, T.D. 
Expression profiling identifies microRNA signature in pancreatic 
cancer. Int. J. Cancer 2007, 120: 1046-1054.  
[74]  Porkka, K.P., Pfeiffer, M.J., Waltering, K.K., Vessella, R.L., Tam-
mela, T.L., Visakorpi, T. MicroRNA expression profiling in pros-
tate cancer. Cancer Res. 2007, 67: 6130-6135.  
[75]  Roldo, C., Missiaglia, E., Hagan, J.P., Falconi, M., Capelli, P., 
Bersani, S., Calin, G.A., Volinia, S., Liu, C.G., Scarpa, A., Croce, 
C.M. MicroRNA expression abnormalities in pancreatic endocrine 
and acinar tumors are associated with distinctive pathologic fea-
tures and clinical behavior. J. Clin. Oncol. 2006, 24: 4677-4684.  
[76]  Bloomston, M., Frankel, W.L., Petrocca, F., Volinia, S., Alder, H., 
Hagan, J.P., Liu, C.G., Bhatt, D., Taccioli, C., Croce, C.M. Mi-
croRNA expression patterns to differentiate pancreatic adenocarci-
noma from normal pancreas and chronic pancreatitis. JAMA 2007, 
297: 1901-1908.  
[77]  Hutvagner, G., Simard, M.J., Mello, C.C., Zamore, P.D. Sequence-
specific inhibition of small RNA function. PLoS Biol. 2004, 2: E98.  
[78]  Meister, G., Landthaler, M., Dorsett, Y., Tuschl, T. Sequence-
specific inhibition of microRNA- and siRNA-induced RNA silenc-
ing. RNA 2004, 10: 544-550.  
[79]  Orom, U.A., Kauppinen, S., Lund, A.H. LNA-modified oligonu-
cleotides mediate specific inhibition of microRNA function. Gene 
2006, 372: 137-141.  
[80]  Krutzfeldt, J., Rajewsky, N., Braich, R., Rajeev, K.G., Tuschl, T., 
Manoharan, M., Stoffel, M. Silencing of microRNAs in vivo with 
'antagomirs'. Nature 2005, 438: 685-689.  
[81]  Johnson, C.D., Esquela-Kerscher, A., Stefani, G., Byrom, M., 
Kelnar, K., Ovcharenko, D., Wilson, M., Wang, X., Shelton, J., 
Shingara, J., Chin, L., Brown, D., Slack, F.J. The let-7 microRNA 
represses cell proliferation pathways in human cells. Cancer Res. 
2007, 67: 7713-7722.  
[82]  Tsuda, N., Ishiyama, S., Li, Y., Ioannides, C.G., Abbruzzese, J.L., 
Chang, D.Z. Synthetic microRNA designed to target glioma-
associated antigen 1 transcription factor inhibits division and in-
duces late apoptosis in pancreatic tumor cells. Clin. Cancer Res. 
2006, 12: 6557-6564.  
[83]  Weidhaas, J.B., Babar, I., Nallur, S.M., Trang, P., Roush, S., 
Boehm, M., Gillespie, E., Slack, F.J. MicroRNAs as potential 
agents to alter resistance to cytotoxic anticancer therapy. Cancer 
Res. 2007, 67: 11111-11116.  
[84]  Rossi, L., Bonmassar, E., Faraoni, I. Modification of miR gene 
expression pattern in human colon cancer cells following exposure 
to 5-fluorouracil in vitro. Pharmacol. Res. 2007, 56: 248-253.  
[85]  Blenkiron, C., Miska, E.A. miRNAs in cancer: approaches, aetiol-
ogy, diagnostics and therapy. Hum. Mol. Genet. 2007, 16 Spec No 
1: R106-R113.  
 
 
 